The Antiphospholipid Syndrome drugs in development market research report provides comprehensive information on the therapeutics under development for Antiphospholipid Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Antiphospholipid Syndrome. Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Antiphospholipid Syndrome and features dormant and discontinued products.

GlobalData tracks ten drugs in development for Antiphospholipid Syndrome by ten companies/universities/institutes. The top development phase for Antiphospholipid Syndrome is preclinical with six drugs in that stage. The Antiphospholipid Syndrome pipeline has seven drugs in development by companies and three by universities/ institutes. Some of the companies in the Antiphospholipid Syndrome pipeline products market are: Johnson & Johnson, University College London and Akari Therapeutics.

The key targets in the Antiphospholipid Syndrome pipeline products market include Beta 2 Glycoprotein 1 (APC Inhibitor or Activated Protein C Binding Protein or Anticardiolipin Cofactor or Apolipoprotein H or APOH), ADP Ribosyl Cyclase/Cyclic ADP Ribose Hydrolase 1 (Cyclic ADP Ribose Hydrolase 1 or T10 or 2′ Phospho ADP Ribosyl Cyclase/2′ Phospho Cyclic ADP Ribose Transferase or ADP Ribosyl Cyclase 1 or CD38 or EC 3.2.2.6 or EC 2.4.99.20), and Cells Expressing ADP Ribosyl Cyclase/Cyclic ADP Ribose Hydrolase 1 (Cyclic ADP Ribose Hydrolase 1 or T10 or 2′ Phospho ADP Ribosyl Cyclase/2′ Phospho Cyclic ADP Ribose Transferase or ADP Ribosyl Cyclase 1 or CD38 or EC 3.2.2.6 or EC 2.4.99.20).

The key mechanisms of action in the Antiphospholipid Syndrome pipeline product include Vitamin K Epoxide Reductase (Warfarin Sensitive) (EC 1.17.4.4) Inhibitor with one drug in Discovery. The Antiphospholipid Syndrome pipeline products include seven routes of administration with the top ROA being Subcutaneous and five key molecule types in the Antiphospholipid Syndrome pipeline products market including Monoclonal Antibody, and Small Molecule.

Antiphospholipid Syndrome overview

Antiphospholipid syndrome (APS) is known also Hughes syndrome. It is an autoimmune disorder characterized by an increased tendency to form abnormal blood clots (thromboses) that can block blood vessels. In APS, the immune system produces abnormal antiphospholipid antibodies that target proteins attached to fat molecules. For diagnosis of antiphospholipid syndrome, the antibodies must appear in blood at least twice, in tests conducted 12 or more weeks apart. Heparin and warfarin are commonly used to treat APS.

For a complete picture of Antiphospholipid Syndrome’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.